-
Innovation Ranking
NewInnovation Ranking – Sorrento Therapeutics Inc
Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works...
-
Company Insights
Innovation and Patenting activity of Sorrento Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Sorrento Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrasimod in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etrasimod in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etrasimod in Atopic Dermatitis (Atopic Eczema) Drug Details: Etrasimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Penile Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Penile Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Penile Cancer Drug Details: Cabozantinib s-malate (XL184, BMS907351,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAC-1 in Pancreatic Endocrine Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAC-1 in Pancreatic Endocrine Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAC-1 in Pancreatic Endocrine Tumor Drug Details: PAC-1 (also known...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Hypopharyngeal Cancer Drug Details: Ruxolitinib (INCB18424, Jakafi,...
-
Product Insights
Clear Cell Squamous Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Clear Cell Squamous Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Clear Cell Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Clear Cell Squamous Cell Carcinoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and...
-
Product Insights
Hairy Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hairy Cell Leukemia - Drugs In Development, 2023’, provides an overview of the Hairy Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chordoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Chordoma - Drugs In Development, 2023’, provides an overview of the Chordoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chordoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...